We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tekcapital Plc | LSE:TEK | London | Ordinary Share | GB00BKXGY798 | ORD �0.004 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.15 | 7.80 | 8.50 | 8.15 | 8.15 | 8.15 | 69,190 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Computer Programming Service | 615k | -12.75M | -0.0715 | -1.14 | 14.52M |
According to the FDA, these targets were introduced “to provide measurable voluntary short-term (2.5-year) goals for sodium content in commercially processed, packaged, and prepared foods to reduce excess population sodium intake.”i
Dr. Jennifer Ashton, ABC News chief medical correspondent said “The news from acting FDA Commissioner Janet Woodcock and Susan T. Mayne, director of the FDA's Center for Food Safety and Applied Nutrition, could be the biggest, most important intervention in a generation for public health."ii
This is a significant milestone for Salarius for the following reasons:
MicroSalt aims to revolutionize the food industry with its patented sodium microparticle, that delivers the full-flavour experience of salt with roughly half the sodium. MicroSalt’s salt particles are approximately 100 times smaller than regular table salt, allowing them to rapidly dissolve, producing a large sensation of saltiness. MicroSalt® is all-natural, non-GMO, and Kosher.
“We’re very excited to see the FDA take a leadership role in encouraging the food industry to embark on meaningful sodium reduction programs for their products,” said Victor Hugo Manzanilla, CEO of MicroSalt. “This is a major milestone for the country, and we are ready to partner with food manufacturers to help them comply with the new guidelines whilst maintaining the full-flavour of their snacks.”
About Salarius Ltd.Salarius, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.
To learn more about MicroSalt please visit https://Salarius.co/.To learn more about SaltMe! snacks please visit https://saltme.com/.
Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.
About Tekcapital plc Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
Forward Looking Statements & DisclaimerThis press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Tekcapital that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, on social media, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Tekcapital’s management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Forward-looking statements express, as at the date of this release, the Company’s plans, estimates, valuations, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance. Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company’s control, including those associated with COVID-19, and there can be no assurance that such statements will prove to be accurate. No assurance is given that such forward looking statements or views are correct or that the objectives of the Company will be achieved. Further, valuations of Company’s portfolio investments and net asset value can and will fluctuate over time due to a variety of factors and this could have a material negative impact on the Company’s financial performance. Tekcapital neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which may differ from those anticipated.
i https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-voluntary-sodium-reduction-goals
ii https://www.goodmorningamerica.com/food/story/fda-recommends-restaurants-food-manufacturers-cut-back-salt-80554477
For further information, please contact: Tekcapital Plc Via Skyline Clifford M. Gross, Ph.D. Skyline Corporate Communications Group, LLC (U.S.) Matthew Abenante/Scott Powell +1 646 893 5835
1 Year Tekcapital Chart |
1 Month Tekcapital Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions